Seegene Expands Operations in Europe with New Subsidiary in France

Seegene Enters the French Market

Seegene, Inc., a prominent global player in the field of molecular diagnostics (MDx), has made a significant move by establishing a new subsidiary in France. This strategic step, announced on December 5, 2025, aims to amplify Seegene’s presence in Europe and support its global sales expansion. France has emerged as a promising market for Seegene, being the second-largest MDx market in Europe after Germany. This newly formed subsidiary will focus on improving local collaborations with customers and partners through enhanced technical support, market development, and engagement with stakeholders in the healthcare sector.

According to research firm Grand View Research, the French MDx market is projected to reach approximately €600 million, accounting for about 15% of the total European market. The demand for diagnostic tests related to sexually transmitted infections (STIs), gastrointestinal infections, and respiratory viruses in France is particularly robust. Through its new subsidiary, Seegene intends to accelerate the sales of these existing product lines while also introducing a broader portfolio that includes cervical cancer diagnostics and other multiplex diagnostic categories.

Daniel Shin, Executive Vice President and Director of Global Sales and Marketing at Seegene, emphasized that the ability to rapidly deliver innovative products and address laboratory efficiency needs is a key competitive factor in France’s dual public and private healthcare market. He noted that the new subsidiary would better equip Seegene to understand the French healthcare system, enhance local customer service, and expedite business growth in the in vitro diagnostics sector with specialized local expertise.

The establishment of this subsidiary also provides strategic support for the European introduction of Seegene's developing solutions, CURECA™ and STAgora™. CURECA™ is a fully automated, unattended PCR (polymerase chain reaction) system, while STAgora™ is a real-time diagnostic data analysis platform that offers predictive insights.

With the addition of the French subsidiary, Seegene now boasts eight foreign sales subsidiaries, complementing a global distribution network comprising 90 distributors across 94 countries. In the first half of 2025, foreign sales accounted for about 93% of Seegene's total revenues, with Europe contributing 63%. This region continues to be a critical growth engine for the company's global expansion efforts.

It's noteworthy that CURECA™ and STAgora™ are still under development and are not yet available for diagnostic purposes.

About Seegene

With over 25 years of experience in research and development, manufacturing, and business related to syndromic real-time PCR technologies, Seegene has demonstrated its expertise particularly during the COVID-19 pandemic. The company has provided more than 340 million COVID-19 tests to over 100 countries worldwide. One of the significant advantages of Seegene's syndromic real-time PCR technology is its capability to simultaneously test for 14 pathogens causing similar symptoms in a single tube, providing quantitative information.

For more information, visit Seegene.com and follow us on LinkedIn.